BioTelemetry, Inc.

Royal Philips ’ Frans van Houten had to display his pragmatic best when the company announced 2021 sales and earnings that were nothing like those anticipated a year ago. Even deep into the second qua

“I would never have thought 2021 would turn out as it did,” said John Babitt, a Minneapolis-based partner with EY. He was referring to the uncharted heights achieved last year in medtech M&A deal-maki

The top 15 cardiovascular device makers included in the most recent Medtech 100 rankings are on track to return to their pre-pandemic growth rates and strategies by the end of 2022, but COVID-19 has

The top themes and talking points that will influence medtech decision-making and operating conditions in 2022 are listed below. A Consolidating Industry Where Major M&A Continues Apace Although there